Curis, Inc. (NASDAQ:CRIS)

CAPS Rating: 3 out of 5

A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer.

Featured Broker Partners


Advertisement